Recruiting

eSight Go

Sponsor:

Brooks Rehabilitation

Code:

NCT07149259

Conditions

Low Vision Aids

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

At Home Use

Study Details

Brief summary:

This research aims to test the updated version of Gentex's device, eSight Go, an image enhancing wearable device to assist those with vision impairments limiting activities of daily living.

Conditions

Low Vision Aids

Study ID

NCT07149259

Start date

Jun 18, 2025

Status verified date

Oct, 2026

Completion date

Dec 31, 2027

Anticipated

Primary completion date

Dec 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Aged 18 to 90.
  • Best-corrected visual acuity between 20/50 to 20/400 in the better eye.
  • Subjects who have been diagnosed with an ocular condition causing visual impairment
  • Have a functional binocular field of view of at least 20 degrees.
  • Visual status stable for at least six months.
  • Demonstrate visual benefit from magnification.
  • Agree to wear the eSight Go in a variety of situations in the home and community.
  • Score ≥ 20 on the Short Orientation-Memory-Concentration Test of Cognitive Impairment (OMCT).
  • Subject must be able to provide an informed consent
  • Subject must agree to use eSight Eyewear only under conditions that will not jeopardize the safety of either the user or the device.

Exclusion Criteria:

  • Participant must not be currently undergoing any medical or surgical procedures resulting in unstable vision.
  • Participants who have undergone cataract, refractive, or other surgical procedures related to vision in the six-month period prior to study enrollment.
  • Severe (>20/400) visual impairment in the better seeing eye.
  • Cognitive limitations (< 20 on OMCT).
  • Participants who have undergone any vision-related injections (e.g. anti-VEGF) in the two-month period prior to the study because of active bleeding in the retina. Ongoing anti-VEGF treatments are permitted if the participant is in a "Treat and Extend" or pro re nata ("PRN") disease management, and macula is dry.
  • Participants are unable or unwilling to adhere to the examination schedules as they are described in the study protocol. This may also include participants already enrolled, who for whatever reason, have become unable or unwilling to continue the study. This may also include participants for whom the travel time to/from the study site is unacceptable.
  • Participants who self-report a history of alcoholism, drug abuse, or psychosis.
  • Participants who exhibit clinical evidence of depression, poor motivation, emotional or intellectual problems, or any other conditions which would likely limit validity of consent or appropriate responses to participate in the study or who are deemed unsuitable psychologically or physiologically for study participation by the investigator.
  • Participants who may have a conflict of interest with eSight Corp, which could reasonably influence their participation in the study.
  • Refractive error outside the range correctable by lens inserts in the device (> +/-8.00 D sph or -4.00 cyl)

Study Design

Enrollment

50 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: At Home Device Utilization

eSight Go device will be utilized at home for a total of 4 weeks in environments the participant feels comfortable using it (e.g. home, work, stores).

Interventions

At Home Use

Participants will take the device home for 4 weeks to use in daily living, such as the home and community settings. There will be regular follow-up phone calls once per week from a member of the research team (e.g., an occupational therapist, or low vision therapist) who is familiar with the device to assist with possible troubleshooting as well as device use strategies. The follow up calls will also collect information about device use time and activities. The device will be returned at visit 2.

Primary outcome measure

  • Change in Visual Acuity [ Time Frame: Pre-intervention and post-intervention at 4 weeks ]
  • Change in Reading Performance [ Time Frame: Pre-intervention and post-intervention at 4 weeks ]

Central Contacts and Locations

Central contacts

Taisiya Matev

904-345-8973Taisiya.Matev@brooksrehab.org

Locations

Brooks Rehabilitation

Recruiting

Jacksonville, Florida, United States, 32216

Contacts

Hannah Grimes

904-528-3159hannah.grimes@brooksrehab.org

Principal Investigator:

Katelyn Jordan

More Information

Sponsor

Brooks Rehabilitation

Last update posted

Oct 20, 2026

Last verified

Oct, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-24. This information was provided to ClinicalTrials.gov by Brooks Rehabilitation on 2026-10-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.